The DOI matches its Crossref record; 297 of the 299 references it cites were found in a registry or an index; 98 of the 267 sources its claims cite were checked for support.
Hormonal treatments for endometriosis: The endocrine background
Open accessAbstract
Endometriosis is a benign uterine disorder characterized by menstrual pain and infertility, deeply affecting women's health. It is a chronic disease and requires a long term management. Hormonal drugs are currently the most used for the medical treatment and are based on the endocrine pathogenetic aspects. Estrogen-dependency and progesterone-resistance are the key events which cause the ectopic implantation of endometrial cells, decreasing apoptosis and increasing oxidative stress, inflammation and neuroangiogenesis. Endometriotic cells express AMH, TGF-related growth factors (inhibin, activin, follistatin) CRH and stress related peptides. Endocrine and inflammatory changes explain pain and infertility, and the systemic comorbidities described in these patients, such as autoimmune (thyroiditis, arthritis, allergies), inflammatory (gastrointestinal/urinary diseases) and mental health disorders.The hormonal treatment of endometriosis aims to block of menstruation through an inhibition of hypothalamus-pituitary-ovary axis or by causing a pseudodecidualization with consequent amenorrhea, impairing the progression of endometriotic implants. GnRH agonists and antagonists are effective on endometriosis by acting on pituitary-ovarian function. Progestins are mostly used for long term treatments (dienogest, NETA, MPA) and act on multiple sites of action. Combined oral contraceptives are also used for reducing endometriosis symptoms by inhibiting ovarian function. Clinical trials are currently going on selective progesterone receptor modulators, selective estrogen receptor modulators and aromatase inhibitors. Nowadays, all these hormonal drugs are considered the first-line treatment for women with endometriosis to improve their symptoms, to postpone surgery or to prevent post-surgical disease recurrence. This review aims to provide a comprehensive state-of-the-art on the current and future hormonal treatments for endometriosis, exploring the endocrine background of the disease.
Overview
CoChat Summary
## TL;DR
This review explains how estrogen dependency, progesterone resistance, and broader endocrine/inflammatory changes shape endometriosis and motivate hormonal treatment. It concludes that hormonal therapies are the cornerstone of management for symptom control, delaying surgery, and reducing postoperative recurrence, though they do not cure the disease.
## Key findings
- Endometriosis is described as a chronic disease affecting reproductive-age women, with prevalence reported as 2–10% in women of reproductive age, 30–50% among infertile women, and 5–21% among women with severe pelvic pain.
- The paper identifies estrogen-dependency and progesterone-resistance as the key endocrine events driving ectopic implantation, reduced apoptosis, increased oxidative stress, inflammation, and neuroangiogenesis.
- GnRH agonists improved endometriosis-associated pain; a meta-analysis of 41 trials found them more effective than placebo and as effective as other progestins for pain relief. Treatment for 3–6 months before ART may increase the odds of clinical pregnancy by fourfold.
- Elagolix (a GnRH antagonist) reduced dysmenorrhea and non-menstrual pelvic pain in two multicenter, double-blind, randomized phase 3 trials over 6 months; extension studies reported benefit over 12 months with improved QoL and reduced analgesic use.
- For postoperative prevention, the LNG-IUS and dienogest lowered recurrence: in one study, recurrence at 6 and 12 months was 3.8% and 9.7% in treatment groups versus 32.5% in controls.
- The review notes that progestins are first-choice therapy per ESHRE guidelines and that about two thirds of patients are satisfied with progestins for symptomatic endometriosis.
## Methods
- Narrative review of the endocrine background of endometriosis and the hormonal therapies used or under development.
- Draws on prior studies, including trials, cohort studies, systematic reviews, meta-analyses, and guideline statements, rather than reporting a new primary dataset.
- Synthesizes evidence across endocrine mechanisms, clinical symptoms, comorbidities, and treatments such as progestins, GnRH agonists/antagonists, COCs, SPRMs, SERMs, and aromatase inhibitors.
## Limitations
- Not stated in the paper. The paper does not describe a formal search strategy, inclusion/exclusion criteria, or systematic review methods.
- Not stated in the paper. It does not quantify the strength of evidence across all interventions in a standardized way, beyond citing selected studies and guidelines.
- Evident from the text: as a review, it is dependent on previously published studies and some therapeutic areas are described as having limited data or insufficient data to permit firm conclusions (for example, SPRMs).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
76 Valid · 8 Not valid · 110 Not checked · 20 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“an involvement of this stress pathway in inflammation is suggested [110].”
§ Hormonal treatments for endometriosis: The endocrine background > Other endocrine aspects > HPA axis and stress hormones
What the sources say
- Supportedcites [110] Novembri R, Carrarelli P, Toti P, et al. Urocortin 2 and urocortin 3 in endometriosis: evidence for a possible role in inflammatory response. Mol Hum Reprod. 2011;17(9):587–93. https://doi.org/10.1093/molehr/gar020. source
The Discussion (p. 5) reports that Ucn 2 and Ucn 3 regulate secretion of cytokines involved in endometriosis and describes their endometrial modulation through CRH-R2. The Introduction (p. 2) identifies these neuropeptides with the CRH pathway, so the citing sentence's suggested involvement of a stress pathway in inflammation is supported. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“increased serum cortisol levels were detected in infertile women with endometriosis, especially in those with advanced stage of disease [105].”
§ Hormonal treatments for endometriosis: The endocrine background > Other endocrine aspects > HPA axis and stress hormones
What the sources say
- Supportedcites [105] Lima AP, Moura MD, Rosa e Silva AAM. Prolactin and cortisol levels in women with endometriosis. Brazilian J Med Biol Res. 2006. https://doi.org/10.1590/S0100-879X2006000800015. source
The Cortisol concentrations section reports significantly higher serum cortisol in infertile women with stage III–IV endometriosis than in fertile women without endometriosis; women with stage I–II disease had intermediate values. The Discussion also identifies the significant elevation in the advanced-stage group. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a blunted early morning cortisol response to CRH test was associated with greater menstrual and non-menstrual pain in endometriosis [101].”
§ Hormonal treatments for endometriosis: The endocrine background > Other endocrine aspects > HPA axis and stress hormones
What the sources say
- Partly supportedcites [101] Ortiz R, Gemmill JAL, Sinaii N, et al. Hypothalamic-Pituitary-Adrenal Axis Responses in Women with Endometriosis-Related Chronic Pelvic Pain. Reprod Sci. 2020. https://doi.org/10.1007/s43032-020-00201-x. sourceExperimental — accuracy not yet measured
The Discussion reports that a blunted response to early-morning CRH testing was associated with greater menstrual and non-menstrual pain, but this finding came from an analysis restricted to non-black participants that combined women with and without biopsy-confirmed endometriosis. The paper does not establish the association specifically for women with endometriosis or for the full study population. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Clear data show that endometriotic tissue expresses the entire set of steroidogenic genes, including aromatase, allowing to local de-novo estradiol (E2) production. [33]”
§ Hormonal treatments for endometriosis: The endocrine background > Endocrine changes in endometriosis > HPO axis hormones
What the sources say
- Supportedcites [33] Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019. https://doi.org/10.1210/er.2018-00242. source
The supplied passage labeled Abstract states that endometriotic tissue expresses the complete set of steroidogenic genes, including aromatase, allowing local conversion of cholesterol to estradiol. This directly supports the claim of local de novo estradiol production. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Autoimmune thyroid disorders are frequently found in endometriosis patients”
§ Hormonal treatments for endometriosis: The endocrine background > Other endocrine aspects > Thyroid hormones
What the sources say
- Not checked — no full text of the sourcecites [113] Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17(10):2715–24. https://doi.org/10.1093/humrep/17.10.2715. source
- Not checked — no full text of the sourcecites [114] Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab. 2008;4(7):394–405. https://doi.org/10.1038/ncpendmet0846. source
- Partly supportedcites [115] Yuk JS, Park EJ, Seo YS, Kim HJ, Kwon SY, Park WI. Graves disease is associated with endometriosis: A 3-year population-based cross-sectional study. Med (United States). 2016;95(10):1–5. https://doi.org/10.1097/MD.0000000000002975. sourceExperimental — accuracy not yet measured
The Discussion reports a higher prevalence of Graves disease, an autoimmune thyroid disorder, among women with endometriosis than among controls. But the Results found no significant association for autoimmune hypothyroidism, so the paper does not support the broader claim that autoimmune thyroid disorders generally are frequently found in endometriosis patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
107 more claims · 35 with their cited sources checked
Create a free account to see all 214 claims and every source verdict.
- It may state two separate claims as one. 94
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al., 2021; Vannuccini et al., 2022)”
From Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium (2025) · cites this paper as Vannuccini et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Mousa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol. 2005;46(3):356–60. https://doi.org/10.1097/01.fjc.0000175438.94906.a0.”
Cited work 10.1097/01.fjc.0000175438.94906.a0 · retracted 2023-09-08 · notice 10.1097/fjc.0000000000001471 · this paper published 2021-08-17
Citations
Cites
1 retracted
The Proangiogenic Action of Thyroid Hormone Analogue GC-1 Is Initiated at an Integrin: [RETRACTED]
(2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000175438.94906.a0 · Cited by 85
RetractedCentral sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Pathogenesis and pathophysiology of endometriosis
Burney, R. O., & Giudice, L. C. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.029 · Cited by 1,590 · cited 1×
“Since P4 signaling is required to counteract E2-induced proliferation and to promote decidualization [55], the loss of P4-responsiveness leads to both an increased growth of endometriotic lesions and to a non-receptive endometrium [33, 56].”
BackgroundZondervan, K. T., Becker, C. M., Koga, K., Missmer, S. A., Taylor, R. N., & Viganò, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0008-5 · Cited by 1,257
Fries, E., Hesse, J., Hellhammer, J., & Hellhammer, D. H. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.04.006 · Cited by 1,204 · cited 1×
“A paradoxical hypocortisolism like an adrenal fatigue [98] may exacerbate painful symptoms by reducing the endogenous analgesia associated with stress (stress-induced analgesia) [99] [100].”
BackgroundRethinking mechanisms, diagnosis and management of endometriosis
Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0245-z · Cited by 1,084 · cited 4×
“Based on patient’s symptoms and the desire of pregnancy, an individualized approach aiming to reduce pain, stress, stress-related comorbidities and to improve QoL should be used for an adequate management [1, 21, 25].”
BackgroundMethodInfluentialBulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00242 · Cited by 844
Clinical diagnosis of endometriosis: a call to action
Agarwal, S. K., Chapron, C., Giudice, L. C., Laufer, M. R., Leyland, N., Missmer, S. A., Singh, S. S., & Taylor, H. S. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.12.039 · Cited by 843 · cited 2×
“Since these symptoms are not specific to endometriosis and may be signs of other gynecological or non-gynecological conditions, misdiagnosis or a significant delay in endometriosis identification is frequently reported [17].”
BackgroundKim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774
Research works printed but not linked: 8
- Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med. 2012;30(1):39–45. https://doi.org/10.1055/s-0031-1299596. · DOI · Paper page
- Reis FM, Petraglia F, Taylor RN. Endometriosis: Hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013. https://doi.org/10.1093/humupd/dmt010. · DOI · Paper page
- Han SJ, Jung SY, Wu SP, et al. Estrogen Receptor β Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. Cell. 2015. https://doi.org/10.1016/j.cell.2015.10.034. · DOI · Paper page
- Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012. https://doi.org/10.1016/j.fertnstert.2012.06.029. · DOI · Paper page
- Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019;19(4):343–60. https://doi.org/10.1080/14712598.2019.1581761. · DOI · Paper page
- Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014. https://doi.org/10.1093/humrep/det457. · DOI · Paper page
- Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017. https://doi.org/10.1016/j.ejogrb.2017.02.015. · DOI · Paper page
- Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): Interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019. https://doi.org/10.1186/s12905-019-0758-6. · DOI · Paper page
Cited by
Targeting Oxidative Stress Involved in Endometriosis and Its Pain
Clower, L., Fleshman, T., Geldenhuys, W. J., & Santanam, N. (2022) · Biomolecules · doi:10.3390/biom12081055 · Cited by 145
“Common clinical symptoms include irregular uterine bleeding, painful intercourse (dyspareunia), and painful periods (dysmenorrhea) [6,7].”
BackgroundNutrition in the prevention and treatment of endometriosis: A review
Barnard, N. D., Holtz, D. N., Schmidt, N., Kolipaka, S., Hata, E., Sutton, M., Znayenko‐Miller, T., Hazen, N., Cobb, C., & Kahleová, H. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1089891 · Cited by 126
Endometriosis: Classification, pathophysiology, and treatment options
Pašalić, E., Tambuwala, M. M., & Hromić‐Jahjefendić, A. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154847 · Cited by 133
Hormonal drugs for the treatment of endometriosis
Capezzuoli, T., Rossi, M., Torre, F. L., Vannuccini, S., & Petraglia, F. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102311 · Cited by 91
Self-citationEpigenetic regulation and T-cell responses in endometriosis – something other than autoimmunity
Szukiewicz, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943839 · Cited by 67
Metadata
- Authors
- Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Petraglia, Felice
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2021-08-17
- Volume
- 23
- Issue
- 3
- Pages
- 333-355
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- PMC
- PMC9156507
- OpenAlex
- W3194419458
- Cited by
- 336
- References
- 299
- Citations by year
- 2026: 80 · 2025: 96 · 2024: 75 · 2023: 56 · 2022: 27 · 2021: 2
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Funders
- Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Keywords
- endometriosis, hormone therapy, estrogen dependence, progesterone resistance, GnRH agonist, GnRH antagonist, progestins, combined oral contraceptives, selective progesterone receptor modulators, selective estrogen receptor modulators, aromatase inhibitors, hypothalamic-pituitary-ovarian axis, anti-Müllerian hormone, corticotropin-releasing factor, oxidative stress, inflammation, infertility, dysmenorrhea, comorbidities, recurrence
- MeSH terms
- Endometriosis, Endometrium, Female, Humans, Infertility, Uterine Diseases, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormonal treatments for endometriosis: The endocrine background. https://app.cochat.ai/papers/10.1007/s11154-021-09666-w
- The paper
- Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022). Hormonal treatments for endometriosis: The endocrine background. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-021-09666-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.